Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and Drug Administration approval for marketing -Y 90 ibritumomab tiuxetan and I 131 tositumomab, given as the Zevalin and Bexxar therapeutic regimens, respectively. Both demonstrate high-response rates and durability of remission in the relapsed/refractory disease setting. Data are emerging regarding their utility as initial therapy, and furthermore, they are been investigated for use sequentially with chemotherapy, and in the myeloablative setting. As yet however, how to best use these agents in the clinical disease course remains uncertain.
Introduction
It is in the field of B-cell non-Hodgkin's lymphomas (NHL) that radioimmunotherapy (RIT) has emerged and translated rapidly to being a commercially viable therapeutic modality. The methodology allows delivery of ionising radiation directly to the tumour site, whilst minimising toxicity to normal tissue, by the generation of a construct between a monoclonal antibody and a radioisotope. Two products, both targeting the B-cellassociated CD20 antigen, are now approved by the United States Food and Drug Administration (FDA); the first, Y 90 ibritumomab tiuxetan (Zevalin, Biogen-IDEC Pharmaceuticals, San Diego, CA, USA) was later followed by tositumomab and I 131 tositumomab (here after known as I 131 tositumomab) (Bexxar, GlaxoSmith, Kline, Philadelphia, PA, USA) ( Table 1 ). This review summarizes the characteristics of these agents and the clinical trial experience available to date.
The B-cell NHLs represent a group of diseases with diverse clinical behaviour, which are becoming an increasing burden in terms of incidence. The majority of cases will be accounted for by two histological subtypes in the Western World, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (The Non-Hodgkin's Lymphoma Classification Project, 1997) . The terminology 'indolent' lymphoma is often used to describe the latter and a number of other less common histological forms (FL comprises B70% of this group). Together, these 'indolent' diseases are characterized by a relatively long-median survival; 8-10 years in the case of FL (Gallagher et al., 1986; Horning, 1993) and the clinical course is typically one of multiple disease episodes, punctuated by variable periods of remission. The tumours are sensitive to external beam radiotherapy, as demonstrated by the long-periods of relapse-free survival observed in patients with early stage disease treated with this modality (Mac Manus and Hoppe, 1996) . For the majority of patients however, who have advanced stage disease, an initial policy of observational management is not disadvantageous in the absence of symptoms or organ compromise (Ardeshna et al., 2003) . When therapy is required, most patients will respond to single-agent or combination cytotoxics, however, disease resistance inevitably develops. DLBCL represents the most common of the 'aggressive' lymphomas, a group of disease that are invariably fatal in the absence of immediate therapy.
Key to the success of RIT in B-cell lymphoma has been the target antigen. CD20, a B-cell specific surface antigen, was initially described in 1980 . The pattern of CD20 expression is critical, for although it is present on >95% of malignant B cells and is expressed during normal B-cell development, it is absent from the terminally differentiated plasma cell and those at the earliest stages of B-cell lineage commitment Anderson et al., 1984) . The unconjugated chimeric monoclonal antibody rituximab (Genentech, South San Francisco, CA, USA and Roche, Basel, Switzerland) targeting CD20 has demonstrated significant single agent efficacy in 'indolent' disease (McLaughlin et al., 1998) , but more significantly has resulted in a paradigm shift in the management of B-cell NHL through its use in combination with chemotherapy (Coiffier et al., 2002; Hiddemann et al., 2005; Marcus et al., 2005; Forstpointner et al., 2006; Pfreundschuh et al., 2006) . RIT extends the activity of unconjugated antibody, allowing the delivery of radiation to multiple disease sites, minimizing normal organ toxicity. With effective tumour targeting, radioisotope emissions may result in the death of adjacent antigen-negative cells in the so called crossfire effect. Additionally, the direct effects of antibody-antigen ligation may also be mechanistically important in eliciting cellular cytotoxicity (Tedder et al., 1986; Buchsbaum et al., 1992b; Cragg and Glennie, 2004; Davis et al., 2004) .
Y
90 ibritumomab tiuxetan Y 90 ibritumomab tiuxetan was approved for marketing in 2002 by the FDA, the first in kind, with an indication for the treatment of patients with relapsed or refractory low-grade, follicular or transformed B-cell NHL, including patients that are refractory to rituximab. Ibritumomab is a murine IgG1-k monoclonal, and is the parent from which chimeric rituximab is derived. Covalently bonded is the linker-chelator tiuxetan, which provides high-affinity chelation sites for either Y 90 or In 111 (used for bioimaging). Given that Y 90 is a pure bemitter, therapy may be delivered as a single outpatient administration; however, a two-step regimen is employed using the g-emitting radionuclide In 111 to ensure that there is acceptable biodistribution following serial gamma camera imaging. Dosimetry is unnecessary and does not correlate with haematological toxicity (Wiseman et al., 2002b (Wiseman et al., , 2003 . Patients receive an infusion of rituximab at a dose of 250 mg/m 2 , to optimize tumour targeting, followed by 5.0 mCi In 111 ibritumomab tiuxetan given over 10 min. Although previously, two imaging scans have been acquired at 2-24 and 48-72 h after administration (with an optional third scan at 90-120 h), a recent FDA amendment reduced this requirement to a single scan at 48-72 h. Data from the Zevalin Imaging Registry indicates that the rate of altered biodistribution, which may help identify patients where excessive radiation could be delivered to normal tissue, is actually very low (0.6%) (Conti et al., 2005) , and indeed European studies have not mandated such imaging procedures (Radford et al., 2003; Morschhauser et al., 2004) . The therapeutic dosing is administered on days 7-9, and is again preceded by 250 mg/m 2 rituximab. Radioisotope is not deconjugated from the antibody, thus a fixed weight-dependent dose of 0.4 mCi/Kg of Y 90 (t 1/2 ¼ 64 h) ibritumomab tiuxetan is administered to a maximum dose of 32 mCi. In the presence of relative thrombocytopenia (platelets 100-149 Â 10 9 /l), this is attenuated to 0.3 mCi/Kg.
I
131 tositumomab Tositumomab, formally known as anti-B1, is a murine IgG2a-l monoclonal antibody directed against the CD20 antigen. I 131 (t 1/2 ¼ 8 days) is covalently linked by the iodogen method (Fraker and Speck, 1978) to the tyrosine residues on the monoclonal. Deconjugation may occur, resulting in clearance of free iodine in the urine, determination of residence time is required so that patient-specific therapeutic dosing may be performed. I 131 has dual b-and g-emission properties, allowing both therapy and dosimetry to be performed with a single radioisotope. An unlabelled predose of tositumomab (450 mg) is given on day 0 to saturate nonspecific binding sites and antigen sinks (Buchsbaum et al., 1992a; Kaminski et al., 1993) . This is followed by infusion of a small tracer dose of 5 mCi I 131 tositumomab (35 mg antibody). Whole body gamma camera scans are then obtained, initially within 1 h and repeated at days 2-4 and 6-7. Appropriate biodistribution is determined by visual inspection, and the residence time calculated by plotting background corrected activity as a percentage of initial activity from each acquired study and a line of best-fit drawn. From this the I 131 activity of the for the total body dose may be derived (Wahl, 2003) . The maximum tolerated whole body dose was established as 75 cGy in the phase I study, limited by haematological toxicity, with attenuation to 65 cGy in those patients with relative thrombocytopenia (platelets 100-149 Â 10 9 /l) (Kaminski et al., 1993 (Kaminski et al., , 1996 . The therapeutic step is performed at days 8-14, where a further infusion of unlabelled tositumomab is followed by the patient-specific whole body dose of I 131 tositumomab. Patients receive oral thyroid protection (potassium iodine) throughout the period of administration from day 0 and continuing for 14 days after the therapeutic infusion. Although radiation protection issues mandate that therapy should be given as an inpatient in the UK, in most US states, outpatient administration is permitted (Siegel, 1998) , and practical guidelines for such administrations are available (Siegel et al., 2002; Vose, 2004) . Owing to concerns about Table 1 Properties of FDA approved RIT products available for therapy in B-cell NHL Modified from (Cheson, 2003) and (Stern and Herrmann, 2005) ibritumomab tixuetan, given in the format that we recognize as the commercial product administered today, were published in 1999 (Witzig et al., 1999) . A previous phase I/II with Y 90 -labelled ibritumomab had used ibritumomab before the therapeutic infusion and dosing levels were escalated according to a flat level of total dose of between 20 and 50 mCi, with doses below 40 mCi being found to be nonmyeloablative (Knox et al., 1996) . The study of Witzig et al. (1999) , established that the maximum-tolerated dose was 0.4 mCi/Kg, reduced to 0.3 mCi/Kg in those with a baseline platelet count of between 100 and 149 Â 10 9 /l and replaced the unlabelled ibritumomab with rituximab 250 mg/m 2 given before the dosimetric or therapeutic infusions. In the 51 patients enrolled onto the study (36 on the phase II arm) the overall response rate (ORR) was 67%, with 26% of patients entering complete remission (CR). For patients with 'low-grade' lymphoma the ORR was 82% (CR 26%), compared to 43% (CR 29%) in those that had intermediate grade disease. In logistic regression analysis, low-grade/follicular histology, absence of bone marrow involvement and non-bulky disease were predictors of favourable response. No responses were observed in the small number of patients (n ¼ 3) treated with mantle cell lymphoma (MCL). The estimated median time to progression (TTP) was 12.9 months. Long-term follow-up of this cohort demonstrated that many of these responses were durable, indeed 24% of responders had a TTP of more than 3 years (Gordon et al., 2004) .
In the pivotal phase III study, 143 rituximab naive patients with relapsed or refractory disease were randomized to receive either Y 90 ibritumomab tiuxetan or rituximab administered according to the standard schedule (Witzig et al., 2002b) . The majority of patients enrolled had FL, with 17 non-follicular low-grade lymphomas and 13 patients with disease transformation. The median number of prior therapies was 2 (range 1-6), of which 45% of patients had failed to respond or progressed within 6 months of their last chemotherapy. Groups were well-matched, and the ORR was superior in the Y 90 ibritumomab tiuxetan-treated arm (80%) compared with the control rituximab-treated patients (56%) (P ¼ 0.002). The CR rates were also superior 30 and 16%, respectively (P ¼ 0.04). For those patients with follicular histology the ORRs were 86 and 56%, respectively (Po0.001), with an ORRs of 67 and 50% in the non-follicular group (P NS). In patients resistant to their last course of chemotherapy, the ORR was higher for Y 90 ibritumomab (64%) compared to rituximab (36%) (P ¼ 0.045).
Despite showing superiority in its primary end point, the advantage of Y 90 ibritumomab tiuxetan did not translate into the time-dependent secondary end points. It should however be noted that the study was not powered to detect such differences. The Kaplan-Meier estimated median TTP was 11.2 months in the Y 90 ibritumomab treat group, and 10.1 months for those treated with rituximab (P NS). Similarly, there was no significant difference in median response duration (14.2 months vs 12.1 months; P NS) or time to next therapy (TTNT) (not reached vs 13.1 months; P NS). In subgroup analysis, a significantly longer TTNT was observed among patients with non-transformed histology (median not reached compared with 13.1 months in the rituximab treated group; P ¼ 0.04). The final results of the study have now been published (Gordon et al., 2003) , demonstrating that TTNT was 21.5 months for patients with FL receiving Y 90 ibritumomab compared to 13.1 months for rituximab; for all patients this was 17.6 months compared to 12.4 months. Similarly, in the FL patients, median TTP was 15.0 months compared to 10.2 months.
A open-labelled phase II was conducted in a patient population with mild thrombocytopenia (platelets 100-149 Â 10 9 /l), receiving Y 90 ibritumomab tiuxetan at a dose of 0.3 mCi/Kg (Wiseman et al., 2002a) . Thirtyeight patients were treated, 25 with FL, having received a median of 2 (range 1-9) previous chemotherapy regimens and 63% with evidence of chemotherapyresistant disease. In this setting the ORR was 83%, with 44% of patients achieving either a CR or CR(u); the ORR in those with follicular histology was 92%. The median TTP was 9.4 months and 12.4 months in responders, extending to 12.6 months in those with FL.
Combined analysis of four registration studies, comprising 211 patients, demonstrated durable response (>12 months) in 78 patients (37%). The characteristics of these patients demonstrated a predominantly follicular histology (76%), although 37% had been refractory to their previous regimen, bulk (defined as X5 cm) was present in 37 and 33% had received at least three previous therapies (Witzig et al., 2003a) . In these individuals, 66% had achieved a CR following Y 90 ibritumomab, and the median TTP was 29.3 months, comparing favourably to a median of 12 months following their previous chemotherapy regimen. tolerated total body dose (Kaminski et al., 1993) and the benefit of predosing with unlabelled antibody, remarkable in this first report of 10 patients, six responded. A later report of 34 patients with mixed histologies confirmed the initial promising activity and documented the durability of some remissions (Kaminski et al., 1996) . Near complete depletion of the B-cell pool was observed, although serum immunoglobulin levels remained unchanged.
A number of phase II studies have confirmed the efficacy and safety of I 131 tositumomab in the relapsed/ refractory disease setting. Vose et al. (2000) reported the first multicentre study from centres in the US and Europe. This study of 47 patients, with either indolent (79%) or transformed disease (21%), validated the practicality and reproducibility of the dosimetric and administration methodology at multiple sites. Patients had been heavily pretreated, having received a median for four prior chemotherapies (range 1-8), the majority had not responded to their last regimen (n ¼ 26) with a median previous response time of only 4 months amongst this cohort. A response was observed in 57% of patients, with a median duration of response of 9.9 months. In 32% of patients, a CR or protocol-specified clinical CR (complete disappearance of all lesions, but an unequivocal statement that the tumour had completely disappeared could not be made) was observed. These individuals in CR had a longer median duration of response at 19.9 months. The response rate was similar in those with indolent disease (57%) and those with transformation (60%). In the 17 patients with bulk disease (defined as an estimate of tumour burden >500 g) the ORR was 59%, and in those with an elevated lactate dehydrogenase (LDH) (n ¼ 18), the ORR was 50%. The methodology of administration was practical, and all site dose calculations were within 10% of those determined at the reference centre.
In 2000, the University of Michigan single centre experience of 59 patients was reported (Kaminski et al., 2000) . This report updated previous efficacy reports (Kaminski et al., 1996; Wahl et al., 1998) of the initial phase I/II and included the first long-term follow-up data. Once again, this was a heavily pretreated population (66% of patients having had Xfour prior therapies), and many had poor risk features. The histological subtypes treated were various, with 47% of patients having 'low-grade' lymphoma, 24% transformed disease and 29% de novo 'intermediate' or 'high-grade' disease. On an intent to treat basis (six patients had dosimetric but no therapeutic dose) the ORR was 71%, with 34% achieving a CR. At a median follow-up of 3.1 years, the median progression free survival (PFS) was 12 months for all responders and 20.3 months for patients that had achieved a CR. In those patients with de novo 'intermediate' or 'high-grade' disease, the response rate was lower (41% compared to 83% for 'low-grade' and transformed), no CRs were achieved and the response duration was short. Responses were seen in all subgroups of patients; a normal LDH and low-tumour bulk predicting for response in univariate analysis.
The 'pivotal' phase III study employed a 'patient-asown-control' design; the primary end point being a comparison of the number of patients that had a longer response to their last chemotherapy (>30 days) to the number of patients who had a longer duration of response after I 131 tositumomab (Kaminski et al., 2001b) . The entry criteria included previous exposure to at least two previous chemotherapy regimens, with failure to respond or relapse within 6 months of their last therapy; all patients had either 'low-grade' (60%) or transformed disease (38%). Given that this population was refractory to chemotherapy, patient demographics report a median of four previous chemotherapies with 71% not responding to their last therapy. In this population options for treatment were limited, accounting for a study design that lacked a concurrent control arm. All investigator-assessed responses were confirmed by an independent masked panel, with a documented ORR to I 131 tositumomab of 65% and a CR rate of 20%. This compared favourably to the ORR of 28% and CR rate of 3% following their last chemotherapy. Seventy-four percent of patients had a longer duration of response to I 131 tositumomab compared with their last chemotherapy regimen (28% equivalent duration), with a median duration of response that was almost twice as long (6.5 months I 131 tositumomab vs 3.5 months last chemotherapy) and a median progression free survival PFS of 8.4 months for I 131 tositumomab responders. In multivariate analysis, tumour burden (o500 g) and nontransformed disease were significantly associated with a higher-response rate, and low-burden the only variable associated with longer duration of response. These results are remarkable given the documented decline in response rate and duration of response that is observed with successive conventional chemotherapies in this disease group (Johnson et al., 1995) . The most recent update to this trail reports that seven of the 12 patients in who entered CR remain so between 4.9 and 7.2 years following therapy .
Bringing I 131 tositumomab forward in the therapeutic schema to a less heavily pretreated population, the results of a phase II of patients treated at first or second recurrence of indolent or transformed indolent lymphoma have been reported (Davies et al., 2004) . The majority of the 41 patients (71%) had follicular lymphoma, the remaining other indolent histologies (12%) or transformed disease (17%). The ORR was 76% with 49% of patients achieving a CR or CR(u); the later was associated with a prolonged remission duration (median not reached at 3.1 years compared to 1.3 years for all responders), with 11/20 CR/CR(u) patients remaining in remission for a median of 4.1 years at the time of reporting. The highest response rates (79%) were reported in FL, although it is noteworthy that five out of seven patients with transformed disease responded. In the univariate analysis, only bulk disease (tumour diameter X5 cm) predicted for inferior CR rates and relative thrombocytopenia (100-149 Â 10 9 /l) and thus receipt of attenuated whole body dose (65 cGy), elevated b2M and two or more prior chemotherapy regimens were associated with a shorter remission duration.
Although the response rates are in line with those observed with conventional therapies at this stage in the disease course, these were achieved with a therapy administered over just 1 week and with remarkably high-durable CR rate. Analysis of 1177 patients demonstrates that there is a statistically significant decline in response rate, CR and duration of response with successive numbers of prior therapies; durable responses were observed much more frequently when I 131 tositumomab was given early in the disease course ( Figure 1) (Gregory et al., 2005) .
An expanded access programme was initiated at 65 institutions to establish further efficacy and safety data and also to ensure the practical utility of I 131 tositumomab in the wider community (Leonard et al., 2001) . A total of 475 patients were enrolled with relapsed or refractory disease, with efficacy data reported on 394 patients. The ORR was 59% (26% CR) with a median duration of response of 15 months in a population that had received a median number of two prior therapies. I 131 tositumomab has been the subject of a further phase III study in the relapsed refractory setting to determine the relative contribution of the radioimmunoconjugate to the regimen based upon the observation that unlabelled tositumomab alone resulted in some tumour regressions (Davis et al., 2004) . Seventy-eight patients (median two prior therapies) were randomized to receive the standard I 131 tositumomab therapeutic regimen compared with the identical dosing of unlabelled antibody. Not unsurprisingly, response rates were superior in those patients that received the radioimmunoconjugate (55 vs 19%; P ¼ 0.002), with a significantly higher CR rate (33 vs 8%; P ¼ 0.012) and TTP (6.3 months vs 5.5 months; P ¼ 0.035). Nineteen patients whose disease failed to responded or progress to unlabeled tositumomab were crossed over into the RIT arm; only three of these had responded with no CRs; 68% went on to have a response with 42% entering CR.
Durable responses may be achieved in patients with relapsed/refractory disease Perhaps the most remarkable observation form these trials in relapsed and refractory patients is the durability of response that has been achieved in a proportion of individuals following RIT (Fisher et al., 2005; Wiseman and Witzig, 2005) . Combined analysis of 250 patients entered into the five clinical trials that served as the population for FDA regulatory approval for I 131 tositumomab, identified PFS of X1 year in 32% of patients and X2 years in 21% of patients (Fisher et al., 2005) . Beyond this time only one relapse was observed per 10 person years with an estimated PFS at 5 years of 17%. The observation was not unique to any particular trial. Seventy-seven percent of these patients with a PFS of X1 year had achieved a CR to I 131 tositumomab, despite 43% having had at least four prior regimens, 36% not responding to previous therapy and 63% deemed refractory to their last treatment regimen. Furthermore, patients with disease transformation (23%), stage IV disease (63%) or bulk (49%) were well-represented amongst durable responders. The key to such duration was achieving CR, for all but one of those who had maintained a PR for 12 months or more relapsed within 20 months. Data from 4 Y 90 ibritumomab studies on 211 patients identified 78 (32%) patients with a TTP of X12 months (Wiseman and Witzig, 2005) . The population was similarly poor risk, with 33% having had three or more prior therapies, 37% had failed to respond to their most immediate prior therapy and 30% had bulky disease. Similar to the above study, the majority of patients with durable a responses had achieved a CR (65%). Taken together, these data demonstrate a significant clinical benefit in a subset of patients were expectation of success is poor.
RIT in specific clinical circumstances
Efficacy following previous treatment with rituximab The use of rituximab in the treatment of follicular lymphomas has expanded considerably in recent years based on the results of a number of randomized studies (Hiddemann et al., 2005; Marcus et al., 2005; Forstpointner et al., 2006; van Oers et al., 2006) . This begs the question, what is the efficacy of CD20 targeted RIT in patients that have recurred after exposure to rituximab? There is little to guide us in those patients that have been treated with combined chemoimmunotherapy, however, there is clear evidence for both agents following single-agent rituximab. In the case of I 131 tositumomab, Horning et al. (2005) reported the results of a 40 patient phase II study, comprising patients predominantly with follicular lymphoma. In this population, who had been exposed to a median of four previous lines of chemotherapy, 88% were considered rituximab refractory having either failed to respond or having progressed within 6 months of completion of rituximab. The ORR to I 131 tositumomab was 65, with 38% of patients achieving a confirmed complete remission. In responding patients the median PFS was 10.4 months, reaching 24.5 months in confirmed responders. Prior response to rituximab did not influence the response rate or PFS, however 80% of patients entering CR had either grade 1 or 2 FL and had low-bulk (no mass >5 cm) disease. Witzig et al. (2002a) reported the Y 90 ibritumomab tiuxetan experience in this setting. Analysis for efficacy was reported for 54 patients with follicular lymphoma, all of which had what is considered true rutiximab refractory disease and 74% with tumours X5 cm in diameter. The ORR was 74, with 15% of patients achieving a CR with a median TTP of 8.7 months in responding patients. In terms of efficacy, Y 90 ibritumomab tixuetan's performance was clearly superior to previous rituximab, and compared favourably to the outcome of the patients last chemotherapeutic regimen. One would advise caution in any attempt to draw conclusions regarding efficacy between the two agents in this setting. The patient populations have some important differences in characteristics, however, it is interesting to hypothesis that I 131 tositumomab may hold some advantage given that it is targeting a distinct CD20 epitope to the common epitope shared by rituximab and ibritumomab, and in some way may thus be able to circumvent some of the mechanism of resistance.
Efficacy following previous high-dose chemotherapy with progenitor cell rescue For those patients who suffer disease recurrence after previous treatment with high-dose chemotherapy and progenitor cell rescue, RIT appears to be an option that may safely be considered. From the University of Michigan experience with I 131 tositumomab, 14 of 59 patients had previous myeloablative therapy (Kaminski et al., 2000) . The maximum tolerated whole-body dose was lower than that seen in the population without prior high-dose therapy exposure at 45 cGy, owing to haematological toxicity. The ORR was however, a very respectable 50%, with five patients entering at CR. Experience in 11 patients from St Bartholomew's Hospital also indicates that at 45 cGy, therapy with I 131 tositumomab may also be administered safely to this population (Davies et al., 2005) . In a similar series of heavily pretreated individuals, all eight patients with rituximab refractory disease that had progressed after high-dose therapy, went on to receive Y 90 ibritumomab tiuxetan employing a conventional dosing schedule (Jacobs et al., 2005) . Grade 4 thrombocytopenia (n ¼ 3) and neutropenia (n ¼ 1) was observed, although no patient was in need of blood product support 12 weeks after RIT administration. The study included patients with a mixed bag of histologies, with 50% of patients having DLBCL; none of them responded. A CR was achieved in 1/3 patients with FL. By contrast, the approach of Vose et al. (2003) was to perform a dose-escalation study with Y 90 ibritumomab tixuetan. Sixteen patients were treated in three cohorts, the highest dose administered being 0.2 mCi/kg; in this group, the majority of grade 4 haematological toxicities occurred and contrasts to the experience with full dose, Y 90 ibritumomab tiuxetan reported above. The response rate in the population studies was 45%. The reduced dose of 0.2 mCi/kg has been taken forward for further investigation.
Efficacy at the time of disease transformation Histological transformation of follicular lymphoma to a more aggressive subtype, most typical diffuse large Bcell lymphoma is a clear adverse prognostic factor in the clinical history of the disease (Johnson et al., 1995) . Response to chemotherapy in transformed disease is typically poor, with outcomes inferior to the de novo disease counterparts (Armitage et al., 1981) and in the main, survival is short (Cullen et al., 1979; Hubbard et al., 1982; Bastion et al., 1997) . Zelenetz et al. (2002) presented a combined analysis, from a number of clinical trails, of 71 patients with transformation of 'indolent' lymphoma that received I 131 tositumomab. The headline ORR in this setting was 39%, despite a population typically with many additional adverse prognostic features including an elevated LDH, disease bulk and high IPI. Responses were durable, at a median of 20 months, and for the 25% of patients entering CR it was 36.5 months. There is some word of caution in the interpretation of these data, the median time from documented transformation to therapy was long at 21 months, suggesting perhaps a more favourable patient profile. Although a smaller data set, the efficacy of Y 90 ibritumomab tiuxetan appears similar, with an ORR of 53% (CR 13%) in 15 patients with transformed disease summated from four of the clinical studies . The median TTP for responders was 8.5 months, with two of the patients remaining in remission over 30 months from therapy.
Efficacy in aggressive B-cell lymphoma histologies
Efficacy in the early phase I/II studies of I 131 tostiumomab at non-myeloablative dosing was disappointing in aggressive histologies, with no CRs achieved and only short-lived benefit observed in responders Kaminski et al. (2000) . A phase II study of Y 90 ibritumomab tiuxetan was conducted in elderly patients with relapsed or refractory DLBCL; in the refractory setting the response rate was 52%, and 53% among those with recurrent disease Morschhauser et al. (2004) . In patients who had previously been treated with the rituximabcytoxan, hydroxyrubicin (adriamycin), oncovin (vincristine), prednisone (CHOP) regimen, a response was observed in 5/28 patients. In a small numbers of patients with MCL (n ¼ 15), objective responses to Y 90 ibritumomab tiuxetan were observed in five patients, of which three had remained in CR/CR(u) between 123 and 380 days at the time of reporting (Oki et al., 2004) .
Retreatment
Data from the phase I/II single-centre experience at the University of Michigan demonstrated that after initial response, retreatment with I 131 tositumomab at the time of progression could result in a clinically meaningful response Kaminski et al. (2000) . Based upon this and the observation that responses of many years duration had been observed, Kaminski et al. (2005a) investigated the role of retreatment in a wider patient cohort that had either achieved a CR or PR, lasting >3 months, after I 131 tositumomab. From 32 enrolled patients, 28 received both the dosimetric and therapeutic doses; 56% had had a previous CR/CR (unconfirmed (CR(u) ) and the median time from initial I 131 tositumomab to retreatment was 21 months (range 7-73). The ORR was 56%, with 25% of patients entering CR. The median duration of response on retreatment was 15.2 months, having been 13.6 months for their initial therapy. For those patients reaching a CR/CR(u), the median duration of response on retreatment was 35 months. No variable significantly predicted response to retreatment or duration of response. The short-term haematological toxicity was similar in depth and duration to that observed following initial therapy, however either MDS or therapy-related acute myeloid leukaemia (tAML) has been reported in five patients, with an annualized incidence of 5.5% per annum after retreatment. Infusion-related reactions may have been more evident on repeat exposure to I 131 tositumomab, with two patients requiring discontinuation of therapy. Similar to other studies, human anti-mouse antibody (HAMA) developed in 10% of patients. For Y 90 ibritumomab tiuxetan the data are limited, and restricted to just 10 reported patients; therapy is feasible and second responses have been observed (Shah et al., 2006) .
RIT as front-line therapy in B-cell lymphoma
A number of groups have published results of the use of RIT as first-line agents in B-cell lymphoma demonstrating that scheduling RIT early in the clinical course of the disease results in some remarkable efficacy. These data comprise use of RIT as a single agent and also sequenced with chemotherapy. Kaminski et al. (2005b) reported on 76 previously untreated patients with FL, median age 49, and all with p25% BM involvement who received conventional 75 cGy dosing of I 131 tositumomab. Ninety-five per cent of patients responded, with 75% achieving a CR. At 5 years, an estimated 77% of the latter were disease free; the outcome for those whose response was only partial faired less well, all progressing at a median of 0.6 years. From 20 patients who had a polymerase chain reaction (PCR) detectable IGH/BCL2 gene rearrangement at baseline and entered a CR, in 16 cases this was no longer evident at 6 months. These patients had a superior PFS compared with those in whom molecular remission was not achieved. Both tumour bulk (o5 cm) and BM involvement were associated with a decreased CR rate, and BM involvement predicted inferior PFS; in a later analysis the FLIPI did not appear to predict outcome (Kaminski et al., 2006) . Haematological toxicity was less than that reported in studies where I 131 tositumomab has been used in the relapsed setting, although HAMA developed frequently (63% of patients). In a post hoc analysis, those patients with the highest HAMA titres demonstrated inferior PFS (35% compared with 70% at 5 years). It has been commented that this population may represent a selected group with a more favourable prognostic profile (Connors, 2005) ; however, the data are encouraging, and in contrast to conventional cytotoxics, achieved with a therapy that can be administered over the period of just 1 week. Randomized phase III studies are clearly warranted.
An alternative approach has been to use CD20 targeted RIT sequentially after chemotherapy in a bid to improve and consolidate response. This approach is attractive as initial tumour debulking may result in optimal circumstances for RIT success (Kaminski et al., 2000; Davies et al., 2004) , and may also permit clearance of the bone marrow thus improving haematological tolerance. This strategy should also permit RIT in candidates previously ineligible because of heavy marrow infiltrate. The SWOG S9911 protocol administered I 131 tositumomab to untreated patients with stage II X -IV FL following six cycles of conventional CHOP chemotherapy (Press et al., 2003) . Of 90 eligible patients, 86 completed CHOP and 77 both phases. Eighty-one (90%) had a documented response following CHOP plus I 131 tositumomab; 54% entered a CR and 12% had an unconfirmed CR. The addition of I 131 tositumomab improved the best response in 57% of patients who were not in CR after CHOP (49% from PR/CR(u) to CR and 9% from CR(u) to CR). Toxicity following RIT was generally milder than following CHOP. Recently, longterm follow-up data for this study have been published (median 5.1 years), reporting estimated PFS and overall survival (OS) of 67 and 87%, respectively at 5 years (Press et al., 2006) . These figures were compared with an historical control population of patients treated with CHOP alone in previous SWOG studies; an absolute benefit of 23% in both PFS and OS was seen in those patients treated sequentially with I 131 tositumomab following CHOP. Comparisons with historical populations are fraught with confounders, and thus an Intergroup phase III study is currently underway to compared six cycles of CHOP with concurrent rituximab against CHOP Â 6 followed by I 131 tositumomab. Planed accrual is 500 patients. Late toxicity using the sequenced approach has been low, with one case only of therapy-related myelodysplasia (tMDS) and 9% of patients developing an elevated thyroid-stimulating hormone (TSH). Leonard et al. (2005) have used three cycles of fludarabine as debulking chemotherapy before I 131 tositumomab. This abbreviated fludarabine chemotherapy course was chosen for acceptable tolerability and efficacy in indolent NHL. Furthermore, in vivo synergy with I 131 tositumomab favours fludarabine over alkyators (Johnson and Press, 2000) and the immunosuppressant properties of fludarabine could potentially reduce the incidence of HAMA development. In 35 patients, the ORR following fludarabine was 89%, increasing to 100% following administration of I 131 tositumomab. Only 9% of these were in a CR after chemotherapy, increasing to 86% on completion of both phases. The estimated 5-year progression-free survival was 56%; for those patients harbouring an IGH/BCL2 translocation, PFS was improved if they were rendered PCR negative. In contrast to single agent I 131 tositumomab as first-line therapy (Kaminski et al., 2005b) , the addition of Fludarabine suppressed HAMA formation with an incidence of only 6% in this study. One patient, with disease progression, developed MDS at 58 months after initial therapy. The results of a regimen comprising six cycles CVP followed by I 131 tositumomab has been reported in abstract form (Link et al., 2004) . The ORR in 30 patients with stage II X -IV previously untreated FL was similarly high at 100%, with the CR rate increasing from 50% following CVP to 80% following I 131 tositumomab; at a median follow-up of 2.3 years, 77% of patients remained in continued remission.
There is less data in the first line setting for Y 90 ibritumomab tiuxetan, all reported in abstract. In a randomised phase III study of untreated FL patients Y 90 ibritumomab tiuxetan consolidation thereby is feasible and well tolerated following chemotherapy induction, the efficacy of such an approach is awaited (Radford et al., 2003) . In 40 patients with FL, 4 weekly infusions of rituximab were followed by three cycles of conventional R-CHOP with a resulting ORR of 100% (Shipley et al., 2005) . After 5 weeks, Y 90 ibritumomab tiuxetan was administered to responders, increasing the CR rate from 28 to 67%; at 2 years, PFS was 77%. The use of single-agent upfront Y 90 ibritumomab tiuxetan has been reported in only a very few number of patients to date (Sweetenham et al., 2004) , although the response rate is encouraging. In untreated MCL, early results of the ECOG E1499 study have demonstrated a significant improvement in the ORR and CR rates achieved after four cycles of R-CHOP by the subsequent delivery of Y 90 ibritumomab tiuxetan (CR from 14 to 45%) (Smith et al., 2006) .
In contrast to the above sequencing strategies, RIT followed by chemotherapy has been investigated in MCL (Zelenetz et al., 2006) . The response rate to RIT was high at 83%, with some improvement in the CR rate following administration of CHOP; this was however inactive at eliminating minimal residual disease.
Ability to tolerate subsequent therapy after RIT It is a matter of concern that further cytotoxic therapy may be subsequently delivered to patients previously exposed to RIT without adverse toxicity or a need to compromise dosing because of diminished marrow reserve. Such considerations are particularly of importance when therapy is applied early in the disease course. There are some data sets that are available when considering such a question, although they suffer as a result of being relatively small, typically single-centre experiences and are based upon patients who, in general, have received RIT later in the disease course (Kaminski et al., 2001a; Ansell et al., 2002; Schilder et al., 2002; Dosik et al., 2006) . From the Mayo Clinic, data are reported from 58 patients who received Y 90 tiuxetan ibritumomab on a number or experimental protocols (Ansell et al., 2002) . A wide range of cytotoxic therapies were administered, patients receiving a median of two (range 1-7) subsequent regimens. In only two patients was the dose of cytotoxic therapy reduced owing to cytopenias. Included in the population were eight patients who underwent a high-dose chemotherapy procedure with autologous progenitor cell rescue. In all but one of these cases, adequate numbers of progenitor cells could be harvested using growth factor mobilization alone and a peripheral harvest. Compared to a 'matched' control group, treated with the same regimen at the same time point in their illness, there was no difference in the rate of grade 4 cytopenias, episodes of febrile neutropenia, transfusion requirements or use of G-CSF. From Cornell University, experience in 68 patients treated with I 131 tositumomab who failed to respond or progressed after therapy is reported (Dosik et al., 2006) . Sixty-five per cent of these patients went on to a range of subsequent cytotoxic therapies including anthracyclines, platiniums, fludarabine and both autologous and allogeneic stem cell transplantation. From the presented data it appears that blood count did not appear to compromise the deliver of therapy. In the remaining 35% of patients, 13 had no further therapy and 11 either external beam radiation or rituximab. Analyses of these patients indicate that in >90% of cases, the decision not to administer cytotoxic therapy was not a reflection of concerns about potential haematological toxicity, but more a reflection of disease status. Data published in abstract form suggest that treatment is well tolerated following the use of I 131 tositumomab as first-line therapy; the report is very preliminary however, yet only one of 22 patients required discontinuation of therapy owing to cytopenias (Kaminski et al., 2001a) . The overall summation is that subsequent therapy may be safely delivered following RIT without compromise on delivery or excessive toxicity; however, there is a clear need for additional data in this field.
Radioresistance may develop in cells that have been exposed to chronic low-dose irradiation, thus introducing similar concern regarding the efficacy of external beam radiotherapy following RIT. Justice et al. (2006) have addressed this in their report of 19 patients who had previously been exposed to Y 90 ibritumomab and developed symptomatic recurrences requiring palliative RIT . The response rate from 29 treated sites was 90%, with a CR rate of 41% and indeed in bulky sites the ORR was similarly high. There appeared to be no significant increase in the severity of adverse events.
Incorporation of RIT into myeloablative regimens with progenitor cell rescue
High-dose chemotherapy with or without total body irradiation (TBI) has come to play a major role in the management of malignant lymphoma. In 'aggressive' lymphoma, the benefit of such an approach has been demonstrated to be superior to conventional salvage chemotherapy in patients with relapsed disease (Philip et al., 1995) and has an accepted role in those patients whose disease is primary refractory to conventional therapy (Vose et al., 1993; Shipp et al., 1999) . In follicular lymphoma, long-term freedom from recurrence may be achieved in those with recurrent disease (Freedman et al., 1999; Apostolidis et al., 2000; Hunault-Berger et al., 2002) , and indeed in a randomized study an advantage in both PFS and OS was demonstrated (Schouten et al., 2003) . However, many patients do not derive long-term benefit from these procedures coupled with concern about their toxicity has necessitated an urgent need for an improved approach. The incorporation of RIT into preparative regimens therefore holds a significant attraction over TBI; with a targeted approach higher doses of ionizing radiation may be delivered to the tumour sites, while sparing normal organ toxicity. The investigative approach has been two pronged, looking at high-dose RIT as a single agent with progenitor cell rescue and also in combination with conventional cytotoxic therapy.
The myeloablative approach was pioneered by Press et al. (1993) publishing the results of a phase I dose escalation study in 1993. Given as a single agent, I 131 tositumomab, with progenitor cell rescue, was dose escalated to a maximum dose of 27.25 Gy to normal organs, limited by cardiopulmonary toxicity. Remarkably in the 19 patients who had favourable biodistribution, defined by higher absorbed doses to the tumour than critical organs, a CR was achieved in 84% of patients with a median duration of response of 11 months. Antibody distribution was favourable in those patients with low-tumour burdens and without splenomegaly. On the basis of these results, a phase II study was conducted in 25 patients, predominantly with follicular lymphoma, to receive a therapeutic infusion calculated to deliver 25-31 Gy to the normal organ receiving the greatest dose of radiation (Press et al., 1995) . Of the 21 patients given a therapeutic infusion (19 with progenitor cell rescue), 16 achieved a CR and two a PR, with 81% of patients progression free at a median follow-up of 12 months. Reporting back on long-term follow up of patients in these two trials at a median follow-up of 42 months, 12 of 39 patients remained in continuous complete remission, with those patients with indolent lymphoma gaining most from this approach (Liu et al., 1998) . In terms of late toxicity, 60% of patients were found to have an elevated TSH level and two patients had developed myelodysplasia. In a small number of patients, Y 90 ibritumomab tiuxetan has been escalated with progenitor cell support, to 24 Gy to the liver (Flinn et al., 2004) . Toxicity has been haematological, with therapy being delivered as an outpatient; of six evaluable patients, four entered CR; further data are eagerly awaited.
Using multivariable analysis, patients with FL who had received high-dose I 131 tositumomab (n ¼ 27) were compared with those treated with an historical control population treated with conventional high-dose preparative regimens (n ¼ 98) (Gopal et al., 2003) . The populations were generally well matched, although patients with a high IPI and elevated LDH were overrepresent in the RIT group. The unadjusted hazard ration for survival in the RIT group was 0.4 (95% CI: 0.2-0.9; P ¼ 0.02) and 0.6 (95% CI: 0.3-1.0; P ¼ 0.06) for PFS. When adjusted for elevated LDH and the presence of transformed disease, these were 0.3 (95% CI: 0.1-0.7; P ¼ 0.004) and 0.5 (95%CI: 0.-0.9; P ¼ 0.03), respectively. There was no difference in transplant-related toxicity, time to engraftment or late tMDS/tAML.
Based upon the observed relapse rate and the hypothesis that most curative strategies for B-cell lymphoma require a combination of agents, the conventional etoposide, cyclophosphamide and TBI preparative regimen has been investigated in a phase I/ II study with substitution of the TBI for I 131 tositumomab . The target I 131 tositumomab dose was incremented from 20 to 27 Gy followed by infusions of etoposide (60 mg/kg, not given in first cohort) and cyclophosphamide (100 mg/kg), with autologous purged rescue. Fifty-two patients received all facets of the planned administration, of which 73% had FL and 28% either de novo DLBCL or transformed FL. Eight patients had primary refectory disease, two patients chemotherapy-resistant relapse and the remaining 42 had demonstrated chemotherapy sensitivity at recurrence; seven patients had been rejected by other transplant centres as not suitable for an high-dose procedure. The maximal tolerated dose was 25 Gy of I 131 tositumomab, with 23 patients treated at this level. Mucositis, nausea and infection, as expected, were frequent and there were four infection-related deaths. Thirty-one patients were evaluable for response, 18 having been cytoreduced before therapy to a nonevaluable disease state, with an ORR of 87% and CR rate of 77%. The 2 years progression-free survival was 68% with OS at that time being 83%. Comparison with a non-randomized control group that had received TBI in combination with etoposide and cyclophosphamide demonstrated an apparent benefit both for indolent and aggressive disease in favour of the I 131 tositumomab containing regimen, with similar toxicities.
The retrospective experience of 16 patients with MCL treated with the combined chemo-RIT regimen has been reported (Gopal et al., 2002) . This disease is characterized by adverse features, short remission durations and limited median survival (Andersen et al., 2002) . Eleven patients had evaluable disease (five were without radiological evidence of disease before therapy), and of these 91% achieved a CR and 60% a molecular remission. The 3-year OS is reported at 93%, with a PFS of 61% at that time, comparing favourably to results with more conventional regimens.
In a similarly designed phase I/II study, Y 90 ibritumomab tiuxetan was combined with etoposide and cyclophosphamide followed by autologous progenitor cell rescue, with 31/41 patients of mixed histological subtypes completing planned therapy (Nademanee et al., 2005) . The dose of Y 90 ibritumomab tiuxetan was calculated to deliver 10 Gy to normal tissue, with toxicity similar to that observed in similar TBI containing regimens. All of 13 patients with evaluable disease at the time of study entry entered CR, with 2-year estimates of relapse-free survival and OS of 78 and 92%, respectively. In this study, 45% of patients had DLBCL, a much higher proportion than the I 131 tositumomab studies; results in this group were promising.
The above approach to myeloablative therapy require considerable expertise in terms of dosimetry, thus standard non-myeloablative doses of both I 131 tositumomab and Y 90 ibritumomab tiuxetan have used in combination with standard conditioning regimens (Fung et al., 2003; Vose et al., 2005) . After dosimetry, and starting at 0.3 Gy escalating to 0.75 Gy, the therapeutic dose of I 131 tositumomab was given at day À12, with conventional BEAM starting at day À6 to 23 patients in a phase I study . Eleven patients were refractory to primary therapy, and comprised 14 patients with DLBCL, five with MCL and four with grade 3 FL. Both haematological and non-haematological toxicities were similar to those encountered with conventional BEAM, although there was a non-significant trend to and increased frequency of mucositis. The ORR was 65%, and at a median of 38 months follow-up, the event-free survival was 395 with OS of 55%. Two patients developed tMDS, although one remains asymptomatic and the other died as a result of progressive disease. In a similar population of 12 patients treated with 0.4 mCi/kg Y 90 ibritumomab tiuxetan and BEAM, 11 patients remain disease-free at a median follow-up of 9 months (Fung et al., 2003) .
The myeloablative approach in the reported phase I/ II studies is clearly provocative and begs the need for randomized phase III studies. Evaluation of RIT is now underway in reduced intensity allogeneic transplantation (Gopal et al., 2006) .
Safety of RIT
The toxicity profile of these RIT agents has become firmly established during the decade or so of clinical development. Publications from integrated safety databases that span a number of trials (Witzig et al., 2003b; Gregory et al., 2004) , indicate that non-haematological toxicity is typically mild, largely comprising asthenia, nausea and chills. Hypersensitivity reactions at the time of drug infusion occur in small numbers of patients (2% grade 3/4 reactions following I 131 tositumomab, and more frequently occurring during the rituximab infusion at the time of Y90 ibritumomab tiuxetan therapy).
The principle short-term toxicity associated with either RIT regimen is reversible bone marrow suppression. In contrast to cyclical chemotherapy, there is a single haematological nadir observed at 4-6 weeks posttherapy, with recovery (to grade 2) by 9 weeks. The degree of toxicity appears similar; data are summarized in Table 2 . Factors predicting for haematological toxicity include the presence of bone marrow involvement and number of previous therapies (Witzig et al., 2003b; Gregory et al., 2004) . Indeed, very clear correlation between the degree of marrow infiltration and grade III or IV cytopenias has been demonstrated for Y 90 ibritumomab tiuxetan. Despite such toxicity, in the main requirement for blood product support has been low, with acceptable rates of febrile neutropenia. In the elderly population, no significant excess in haematological toxicity is observed Witzig et al., 2003b) , and similarly the degree of myelosuppression is comparable (Kaminski et al., 2005a) following retreatment.
There has been some concern that systemic exposure to radiation may result in an increased frequency of tMDS/tAML following RIT. A review of 1071 patients with 'low-grade' lymphoma treated with I 131 tositumomab identified 35 cases, with a crude incidence of 3.3% and annualized to 1.4% per person year of follow-up (Bennett et al., 2005) . Among 76 patients receiving the agent as initial therapy for FL, no cases were reported, highlighting the role of previous therapies in the development of tMDS/tAML. In an independent review of 25 of the tMDS/tAML cases, 40% were found to have had tMDS before I 131 tositumomab exposure and in 8% of patients there was actually no evidence tMDS; the revised crude incidence was 2.2%, and annualized incidence of 0.9%/year (cumulative incidence of 0.8 and 5.0% at 2 and 5 years, respectively. These figures are in line with the expected frequency based upon their prior chemotherapy; the experience with Y 90 ibritumomab tiuxetan would appear to concur with this observation (Czuczman et al., 2002) . In multivariate analysis, previous exposure to fludarabine containing regimens and a baseline platelet count o150 Â 10 9 l were associated with significantly higher rated of tMDS/tAML. Five patients from the series 349 patients treated with Y 90 ibritumomab tiuextan, and all with previous alkylating agent exposure, have developed tAML/tDMS (annualized incidence 1.1%/year) (Witzig et al., 2003b) .
Despite the use of thyroid blockade with high-doses of iodine at the time of therapy, hypothyroidism is a recognized long-term sequelae following I 131 tositumomab therapy with a cumulative incidence of 8.7% at 2 years and 16.6% at 5 years (Gregory et al., 2004) . HAMA may develop in response to infusion of murine protein; the cumulative incidence was 9.8% at 2 years Data for conventional non-myeloablative dosing and is obtained from both products datasheets. (Gregory et al., 2004) , the majority having developed within 6 months of therapy. The relative immunocompetency of the patient is a major determinant of HAMA development; in the previously untreated patients the rate was very much higher at 63% (Kaminski et al., 2005b) . The consequence of HAMA development is unclear, and does not appear to compromise response to therapy (Davies et al., 2004) . The rate of HAMA is much lower following Y 90 ibritumomab tiuxetan, at 1% (Witzig et al., 2003b) ; in the latter regimen, exposure to murine protein in less.
Conclusions
The addition of RIT has added significantly to our therapeutic armamentarium in the management of Bcell lymphoma, and affords the patient a high chance of achieving a potentially durable remission. They have the advantage of a short administration time with tolerable toxicity; however, their uptake has been slow in the practising community. The reasons for this are complex, but include logistics of administration with the need for coordination between Nuclear Medicine facilities and the Oncologist, cost, issues surrounding reimbursement and concerns about long-term toxicity. It seems likely that as more experience is gathered with their use, we will see a shift towards earlier administration in the disease course and sequentionally with chemotherapy. At present, there is little, except experience, to guide selection of either agent where both are available, however the FDA has mandated a randomized comparison study between Y 90 ibritumomab and I 131 tositumomab, with the aim of recruiting 350 patients with FL. In terms of their use in the myeloablative setting, data is still tantalizing, and phase III studies are starting to progress. Although the exact place for these agents is still being established, newer radioimmunoconjugates are under development. I 131 rituximab has shows significant efficacy in the phase II setting, without immunogenicity (Leahy et al., 2006) , and Y 90 epratuzumab (targeting CD22) is in early phase clinical trials (Chatal et al., 2004) . RIT will continue to emerge as an important tool in the management of NHL.
